Clinical Trial Update: A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

A microdose Phase 1 study of the radiopharmaceutical TTX-MC138-NODAGA-Cu64 in patients with advanced solid tumors has completed. The sponsor is TransCode Therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TTX-MC138-NODAGA-Cu64

Snippet

Sponsor: TransCode Therapeutics | Conditions: Advanced Solid Tumor | EARLY_Phase 1 | Status: COMPLETED